Lorcaserin: a selective serotonin receptor (5-HT2C) agonist for the treatment of obesity


  • Bhaven C. Kataria Department of Pharmacology, C.U. Shah Medical College, Surendranagar 363001, India


Anti-obesity drug, Sibutramine, Orlistat, 5-hydroxytryptamine receptor agonist


Lorcaserin is a selective serotonin receptor (5-HT2C) agonist that recently received the U.S. Food and Drug Administration (FDA) approval for chronic weight management. The efficacy of this drug in reducing body weight and improving metabolic parameters of obese patients has been demonstrated in three phase-3 clinical trials. The available evidence indicates that this drug does not show heart valve abnormalities, and the treatment improves the risk factors for type 2 diabetes and cardiovascular diseases. However, the drug’s manufacturer will be required to conduct postmarketing studies, including a long-term cardiovascular outcomes trial to assess the effect of Lorcaserin on the risk for major adverse cardiac events such as heart attack and stroke.


Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007; 59:151-84.

Rubio MA, Gargallo M, Millan AI, Moreno B. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Public Health Nutr 2007; 10:1200-5.

Bai B, Wang Y. The use of lorcaserin in the management of obesity: a critical appraisal. Drug Des Devel Ther 2010; 5:1-7.

Bello NT, Liang NC. The use of serotonergic drugs to treat obesity - is there any hope? Drug Des Devel Ther 2011; 5:95-109.

Lam DD, Przydzial MJ, Ridley SH, et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 2008; 149:1323-8.

Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S et al. Multicenter, placebo-controlled trial of Lorcaserin for weight management. N Engl J Med 2010; 363:245-56.

Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96:3067-77.

O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J et al. Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study. Obesity (Silver Spring) 2012; 20:1426-36.

Belviq (Lorcaserin hydrochloride) prescribing information. Available at http://us.eisai.com/package_inserts/BelviqPI.pdf. Accessed 29 July 2012.




How to Cite

Kataria, B. C. (2017). Lorcaserin: a selective serotonin receptor (5-HT2C) agonist for the treatment of obesity. International Journal of Basic & Clinical Pharmacology, 1(1), 45–47. Retrieved from https://www.ijbcp.com/index.php/ijbcp/article/view/1398



New Drug Update